StockUS listing USATXIPINKHealthcareValue Trap

Avenue Therapeutics Inc(ATXI) Stock Analysis | Healthcare

USD --+0.00%
Reward39Moderate
Risk38Moderate
75%Data
Thin -207% profit margin
USD —+0.00 (+0.00%) Previous close · PINK
Market cap 1.81M
Reward Ratingⓘ39 Moderate reward assessment · 75% data coverage
Bottom 5% of stocksView factors
Risk Ratingⓘ38 Moderate risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on ATXI to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Avenue Therapeutics Inc?

, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases.

AI Brief Pro

The brief on Avenue Therapeutics Inc

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Avenue Therapeutics Inc?

, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. The company product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; and intravenous tramadol for the treatment of post-operative acute pain. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 1.81M.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (39)
Company Information
SectorHealthcare
IndustryBiotechnology
Beta-0.922
Insider Activity
12M windowQuiet
Fewer than three real open-market insider trades in the last 12 months. Mechanical activity (option exercises, RSU vests) is excluded from the signal.